Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)3.99M
Market Cap
$284.90M
Enterprise Value$876.70M
Total Cash (Recent Filing)$20.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.16
Next Earnings
May 13, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding197,848,890
10 Day Avg. Volume3,823,906
30 Day Avg. Volume3,992,380
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.01
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap3.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda115.83
Forecast
1Y Price Target
$7.20Price Target Upside410.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Esperion News
PremiumCompany Announcements
Esperion Appoints Robert E. Hoffman as New Director
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEsperion's financials show a significant U.S. net product revenue growth of 52% year-over-year in 4Q24.
Market ExpansionEsperion continues to expand the company's global reach across key regions through strategic partnerships.
Pipeline DevelopmentManagement announced ongoing pipeline expansion opportunities, including development of two triple-combination products with anticipated LDL-C lowering of more than 60%.
Bears Say
Growth ChallengesUS growth has showed signs of slowing, with 4Q’s script growth a meaningful decline this early on.
Revenue TrendsRevenue per scripts continued its downward trend, impacted by the initiation of new Medicare contracts.
Sales PerformanceUS sales of bempedoic acid (BA) missed by -$3M (-8%), marking the 3rd consecutive quarter the franchise has come in below.
---
Ownership Overview
0.89% Insiders
18.64% Mutual Funds
27.45% Other Institutional Investors
43.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $1.35 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $284.90M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is May 13, 2025 which is in 41 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Mar 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.149 by $0.039.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.15.
How many shares outstanding does Esperion have?
Esperion has 197,848,890 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.149. Following the earnings report the stock price went up 12.025%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
---
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.20 (410.64% Upside)
$7.20 (410.64% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $29.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.46%
12-Months-Change
Fundamentals
Return on Equity
23.44%
Trailing 12-Months
Asset Growth
67.81%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
---
ESPR Company Deck
---
ESPR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements including FDA label expansions, strong revenue growth, and successful global partnerships. However, challenges such as the impact of the Medicare coverage gap and a slow start to 2025 prescription trends were also noted.Read More>---
ESPR Stock 12 Month Forecast
Average Price Target
$7.20
▲(410.64% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
8/24 ratings generated profit
1 Year Average Return
+20.24%
reiterated a buy rating 30 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +20.24% per trade.
---